In our series, loss of MSH6 expression confers a better prognosis in high-grade astrocytomas treated only with radiotherapy suggesting that MSH6 protein could modulate response to radiation therapy in these tumors. Here, MSH6 is linked to astrocytoma (excluding glioblastoma).